Encouraging safety and preliminary efficacy analysis from the elacestrant and capivasertib Phase 1b regimen of the ELEVATE study will be presented.The…
Data spans seven presentations across both solid tumors and hematologic malignancies, providing updates on the potential benefit these therapies may…
BASEL, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage preclinical biotechnology company focused on reprogramming the immune system…
May 08, 2026 20:45 ET | Source: Amplia Therapuetics Limited Melbourne, Australia, May 08, 2026 (GLOBE NEWSWIRE) -- HIGHLIGHTS Amplia…
Recognition highlights BostonGene's leadership in improving drug development decisions,reducing risk and accelerating patient impactSAN ANTONIO, May 5, 2026 /PRNewswire/ -- Frost &…
Additional funding of €4m from new co-lead investor Biovance Capital, and €1.5m from existing co-lead Kurma Partners, to reach a…
Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric…
Chesterbrook, PA, March 03, 2026 (GLOBE NEWSWIRE) -- Persevere Therapeutics, Inc. (“Persevere”), a Delaware-incorporated, clinical-stage oncology biotechnology company, today announced…
February 24, 2026 16:30 ET | Source: Cardiff Oncology, Inc. Reported positive update from Phase 2 CRDF-004 trial in first-line…
February 12, 2026 21:18 ET | Source: Coherus Oncology, Inc. REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Coherus…